1. Home
  2. KRUS vs REPL Comparison

KRUS vs REPL Comparison

Compare KRUS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

HOLD

Current Price

$48.20

Market Cap

539.2M

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$13.82

Market Cap

454.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRUS
REPL
Founded
2008
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
539.2M
454.6M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
KRUS
REPL
Price
$48.20
$13.82
Analyst Decision
Buy
Hold
Analyst Count
9
9
Target Price
$81.11
$5.67
AVG Volume (30 Days)
222.8K
6.9M
Earning Date
04-07-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
79.75
N/A
EPS
N/A
N/A
Revenue
$282,763,000.00
N/A
Revenue This Year
$20.50
N/A
Revenue Next Year
$20.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.88
N/A
52 Week Low
$42.62
$1.50
52 Week High
$87.99
$13.90

Technical Indicators

Market Signals
Indicator
KRUS
REPL
Relative Strength Index (RSI) 49.67 62.64
Support Level $47.15 $6.80
Resistance Level $50.25 N/A
Average True Range (ATR) 1.92 1.55
MACD 0.43 0.41
Stochastic Oscillator 74.48 95.72

Price Performance

Historical Comparison
KRUS
REPL

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: